Dexlansoprazole

Routes
Oral (PO)
Half-Life (t½)
PO: 1.7h
Formula
C16H14F3N3O2S
Molecular Weight
369.36 g/mol
PubChem CID
9578005
Aliases
Dexilant

Pharmacological Mechanism

R-enantiomer of lansoprazole — proton pump inhibitor with delayed dual-release formulation (peaks at 1–2h and 4–5h) that extends acid suppression vs once-released PPIs. Approved for GERD + erosive esophagitis. CYP2C19 substrate.

Half-Life & Elimination Curve (PO: 1.7h)

100%50%25%12.5%0%0h0×t½1.7h1×t½3.4h2×t½5.1h3×t½6.8h4×t½8.5h5×t½0×t½ (0h): 100% remaining (~0.932 mg/L)1×t½ (1.7h): 50% remaining (~0.466 mg/L)2×t½ (3.4h): 25% remaining (~0.233 mg/L)3×t½ (5.1h): 12.5% remaining (~0.116 mg/L)4×t½ (6.8h): 6.3% remaining (~58.2 µg/L)5×t½ (8.5h): 3.1% remaining (~29.1 µg/L)
Plasma (PO)t½ Decay (1.7h)
  • 0×t½0h100% (0.932 mg/L)
  • 1×t½1.7h50% (0.466 mg/L)
  • 2×t½3.4h25% (0.233 mg/L)
  • 3×t½5.1h12.5% (0.116 mg/L)
  • 4×t½6.8h6.3% (58.2 µg/L)
  • 5×t½8.5h3.1% (29.1 µg/L)
Elimination t½1.7h (PO)
Rate Constant (ke)0.408 h⁻¹
Time to Peak (Tmax)60m
Est. Peak (Cmax)0.932 mg/L
Clearance (CL)12.2 L/h
97% Washout (5×t½)8.5h

Dosing Guidelines

Pharmacokinetic Parameters

Pathways It Modulates

Target Organ Systems

Chemical Structure & Identifiers